Company Overview
| Stock Name | JW Therap-B |
|---|---|
| Stock Code | 02126 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 公司為中國領先的臨床及臨床前階段細胞治療公司,專注於開發、製造和商業化用於血液癌症及實體瘤的突破性細胞免疫療法,主打候選產品為針對復發或難治B細胞淋巴瘤的自體抗CD19 CAR-T療法relma-cel。 |
| Listing Date | 2020-11-03 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海自由貿易試驗區美盛路225號42號樓4樓 |
| Business Address (Hong Kong) | 銅鑼灣勿地臣街1號時代廣場2座31樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.jwtherapeutics.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 23.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 11,900 |
| Par Value | To be extracted |
| Offer Period | 2020-10-22 to 2020-10-28 |
| Global Offering Shares | 97,692,000 shares |
| HK Public Offer Shares (Initial) | 9,770,000 shares (10.0%) |
| Public Offer Lots (Initial) | 19,540lots (Pool A9,770lots,Pool B9,770lots) |
| International Placing Shares (Initial) | 87,922,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 376,176,229 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 50.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 2,325,069,600 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 11,900 |
| 2 lots | 1,000 | HK$ 23,800 |
| 3 lots | 1,500 | HK$ 35,700 |
| 4 lots | 2,000 | HK$ 47,600 |
| 5 lots | 2,500 | HK$ 59,500 |
| 6 lots | 3,000 | HK$ 71,400 |
| 7 lots | 3,500 | HK$ 83,300 |
| 8 lots | 4,000 | HK$ 95,200 |
| 9 lots | 4,500 | HK$ 107,100 |
| 10 lots | 5,000 | HK$ 119,000 |
| 12 lots | 6,000 | HK$ 142,800 |
| 14 lots | 7,000 | HK$ 166,600 |
| 16 lots | 8,000 | HK$ 190,400 |
| 18 lots | 9,000 | HK$ 214,200 |
| 20 lots | 10,000 | HK$ 238,000 |
| 30 lots | 15,000 | HK$ 357,000 |
| 40 lots | 20,000 | HK$ 476,000 |
| 50 lots | 25,000 | HK$ 595,000 |
| 60 lots | 30,000 | HK$ 714,000 |
| 70 lots | 35,000 | HK$ 833,000 |
| 80 lots | 40,000 | HK$ 952,000 |
| 90 lots | 45,000 | HK$ 1,071,000 |
| 100 lots | 50,000 | HK$ 1,190,000 |
| 120 lots | 60,000 | HK$ 1,428,000 |
| 140 lots | 70,000 | HK$ 1,666,000 |
| 160 lots | 80,000 | HK$ 1,904,000 |
| 180 lots | 90,000 | HK$ 2,142,000 |
| 200 lots | 100,000 | HK$ 2,380,000 |
| 400 lots | 200,000 | HK$ 4,760,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 600 lots | 300,000 | HK$ 7,140,000 |
| 800 lots | 400,000 | HK$ 9,520,000 |
| 1,000 lots | 500,000 | HK$ 11,900,000 |
| 1,200 lots | 600,000 | HK$ 14,280,000 |
| 1,400 lots | 700,000 | HK$ 16,660,000 |
| 1,600 lots | 800,000 | HK$ 19,040,000 |
| 1,800 lots | 900,000 | HK$ 21,420,000 |
| 2,000 lots | 1,000,000 | HK$ 23,800,000 |
| 3,000 lots | 1,500,000 | HK$ 35,700,000 |
| 4,000 lots | 2,000,000 | HK$ 47,600,000 |
| 5,000 lots | 2,500,000 | HK$ 59,500,000 |
| 6,000 lots | 3,000,000 | HK$ 71,400,000 |
| 7,000 lots | 3,500,000 | HK$ 83,300,000 |
| 8,000 lots | 4,000,000 | HK$ 95,200,000 |
| 9,770 lots | 4,885,000 | HK$ 116,263,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 937.7M |
| Est. Threshold | HK$ 9.44B |
| Analysis Result | HK market cap below threshold, need +907% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 8,952,994,250 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣633.3百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Balance Sheet
| Item | 2018 | 2019 |
|---|---|---|
| Cash and cash equivalents | 4,539 | 7,796 |
| Total current assets | 5,503 | 9,174 |
| Total assets | 12,642 | 14,962 |
| Total current liabilities | 21,852 | 53,458 |
| Total liabilities | 21,852 | 53,458 |
| Total equity | -9,210 | -38,496 |
| Equity attributable to owners | -9,210 | -38,496 |
Cash Flow Statement
| Item | 2018 | 2019 |
|---|---|---|
| Net cash from operating activities | 0 | -16,350 |
| Net cash from investing activities | -2,341 | -10,319 |
| Net cash from financing activities | 7,918 | 30,687 |
| Net increase in cash | 5,577 | 4,018 |
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 22.0 |
|---|---|
| First Day Open | HK$ 24.35 |
| First Day Change | -7.56% |
| First Day Volume | 48183900.0 |
| First Day Turnover | 1139990000.0 |
| Use of Proceeds | 1、約878.7百萬港元(占所得款項凈額約40.0%)預期將用于我們的核心候選產品relma-cel;
2、約746.9百萬港元(占所得款項凈額的34.0%)預期將用于其他侯選產品;
3、約351.5百萬港元(占所得款項凈額的16.0%)預期將用于潛在管線產品;
4、約219.7百萬港元(占所得款項凈額的10.0%)預期將用于營運資金及一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (4)
Joint Bookrunners (8)
Joint Lead Managers (8)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Aranda Investments Pte. Ltd. | 38,746,400 HKD | — | 1.67% | — | 6 months | 2021-05-03 |
| 2 | AVICT Global Holdings Limited | 116,239,200 HKD | — | 5.00% | — | 6 months | 2021-05-03 |
| 3 | Hillhouse Funds | 77,492,800 HKD | — | 3.33% | — | 6 months | 2021-05-03 |
| 4 | LVC Mi Holding Limited | 77,492,800 HKD | — | 3.33% | — | 6 months | 2021-05-03 |
| 5 | Oaktree Funds | 154,997,500 HKD | — | 6.67% | — | 6 months | 2021-05-03 |
| 6 | Platinum Investment Management Limited | 154,997,500 HKD | — | 6.67% | — | 6 months | 2021-05-03 |
| 7 | Rock Springs Capital Master Fund LP | 154,997,500 HKD | — | 6.67% | — | 6 months | 2021-05-03 |
| 8 | RWC Asset Advisors (US) LLC | 154,997,500 HKD | — | 6.67% | — | 6 months | 2021-05-03 |
| 9 | Veritas Asset Management LLP | 154,997,500 HKD | — | 6.67% | — | 6 months | 2021-05-03 |
| 10 | 太平资产管理(香港)有限公司 | 77,492,800 HKD | — | 3.33% | — | 6 months | 2021-05-03 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 李怡平 | — |
| Company Secretary | 梁雪穎 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 主要股東包括Juno(19.91%)、Syracuse Cayman(12.90%)、WXAT HK(10.16%)、TLS Beta Pte. Ltd.(6.03%)、李醫生(5.79%)及CJW Therapeutics Investment Limited(5.20%)等。 |
|---|




